GE-HEALTHCARE
20.6.2022 09:02:12 CEST | Business Wire | Press release
With most hospitals around the world currently relying on manual “spot-checks” to monitor patient vitals, GE Healthcare unveils Portrait Mobile3 , a wireless patient monitoring system that enables continuous monitoring throughout a patient’s stay. The system helps clinicians detect patient deterioration. Early detection of patient deterioration may help reduce length of stay and intensive care unit (ICU) admissions – and improve patient outcomes4 . Portrait Mobile includes patient-worn wireless sensors which communicate with a mobile monitor.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220616005149/en/
Globally, an estimated 65 percent of hospital patients and over 90 percent of post-acute care patients are monitored manually and not continually.5 Many vital sign changes are missed during spot checks which often occur in four-to-six-hour intervals6 . A UK national audit of adult in-hospital cardiac arrests showed that more than half (57 percent) occurred on the wards and only five percent in the ICU7 where patients are monitored continuously. Most patients who end up in cardiac arrest or critical care, don’t suddenly deteriorate but rather present with earlier vital signs that show abnormal trends8 . Respiratory rate is the highest ranked variable in models predicting clinical deterioration in the hospital9 .
With Portrait Mobile, respiration rate, oxygen saturation and pulse rate for general ward and post-surgery patients can be captured wirelessly, continuously. This innovation allows caregivers to identify changes that may signal that cardiorespiratory complications or infectious disease may be developing. It gives clinicians the opportunity to act early and potentially avert serious adverse events.
“In an evaluation clinical study conducted at a London hospital in the UK, 90 percent of nurses reported that they feel more reassured about their patient’s condition when continuous monitoring is used versus vital signs spot check measuring,” said Erno Muuranto, Engineering Director at GE Healthcare in Finland. “Portrait Mobile provides reliable measurement technology and meaningful alarms in a mobile setting.”
For patients, Portrait Mobile’s wireless continuous monitoring helps with the ability to move about the hospital, without being restricted to the bedside. This also allows visitors to interact with the patient without technology getting in the way. Moreover, the solution provides patients and family members peace of mind knowing that monitoring is constant - even when the patient is out of their room. Patient mobility may help improve patient outcomes and reduce length of stay, which may lower costs and elevate patient satisfaction10 .
Portrait Mobile is designed to be as reliable as wired technology. Its routable communications architecture enables hospitals to leverage their existing network infrastructure when deploying the system, reducing installation and maintenance costs.
Portrait Mobile was developed in Helsinki, GE Healthcare’s global center of excellence for monitoring solutions where engineers have been developing patient monitoring technology for decades. Today, GE monitors are used in hospitals across the world - from Beijing to London, New York, and more.
About GE Healthcare:
GE Healthcare is the $17.7 billion healthcare business of GE (NYSE: GE). As a leading global medical technology, pharmaceutical diagnostics and digital solutions innovator, GE Healthcare enables clinicians to make faster, more informed decisions through intelligent devices, data analytics, applications and services, supported by its Edison intelligence platform. With over 100 years of healthcare industry experience and around 48,000 employees globally, the company operates at the center of an ecosystem working toward precision health, digitizing healthcare, helping drive productivity and improve outcomes for patients, providers, health systems and researchers around the world.
Follow us on Facebook , LinkedIn , Twitter , Instagram and Insights for the latest news, or visit our website www.gehealthcare.com for more information.
_______________________
1
Taenzer, et al., Postoperative Monitoring—The Dartmouth Experience. The Official Journal of the Anesthesia Patient Safety Foundation; Volume 27, No. 1, 1-28 Circulation 94,429 (2012). 15. Brown, et al., Continuous Monitoring
2
https://www.medelahealthcare.com/en-GB/insights/benefits-of-early-patient-mobilization
3
Portrait Mobile is a CE-marked medical device. Portrait Mobile is not 510(k) cleared and not available in all markets.
4
Brown, et al., Continuous Monitoring in an Inpatient Medical-Surgical Unit: A Controlled Clinical Trial. The American Journal of Medicine; Vol. 127, Issue 3, 226–232. 16. Vincent, et al.,
5
https://www.managedhealthcareexecutive.com/view/need-continuous-monitoring-todays-healthcare-system
6
Michard, et al., Protecting ward patients. ICU Management & Practice; Vol 19 – Issue 1 (2019).
7
Nolan JP, Soar J, Smith GB, et al. (2014) Incidence and outcome of in-hospital cardiac arrest in the United Kingdom national cardiac arrest audit. Resuscitation, 2014; 85:987-92.
8
Churpek MM, Yuen TC, Huber MT, et al. (2012) Predicting cardiac arrest on the wards. A nested case-control study. Chest, 141:1170-1176.
9
Loughlin, et al., Respiratory Rate: The Forgotten Vital Sign – Make It Count! Jt Comm J Qual Patient Saf; 44(8) 494-499 (2018).
10
Vincent, et al., Improving detection of patient deterioration in the general hospital ward environment. Eur J Anaesthesiol; 35:325-333 (2018).
View source version on businesswire.com: https://www.businesswire.com/news/home/20220616005149/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Yubico Appoints Poupak Modirassari Enbom as Chief Marketing Officer to Accelerate Global Momentum and Drive Market Leadership30.3.2026 15:00:00 CEST | Press release
Yubico (NASDAQ STOCKHOLM: YUBICO), the creator of the most secure passkeys and a leading provider of hardware authentication security keys, today announced the appointment of Poupak Enbom as Chief Marketing Officer (CMO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330278027/en/ Enbom joins Yubico at a pivotal moment as organizations worldwide accelerate the shift to phishing-resistant authentication and modern identity security in the age of AI. “We’re excited to welcome Poupak to Yubico,” said Jerrod Chong, acting chief executive officer, Yubico. “As the threat landscape evolves with AI-driven attacks and increasing automation, organizations are rethinking how they secure digital identities of both humans and AI agents at scale. She brings a unique combination of technical depth, global leadership, and customer-first mindset that will help us continue to expand our impact and support our customers and partners around
Westinghouse Celebrates Record-breaking 80 Years of Nuclear Fuel Manufacture at Springfields30.3.2026 14:00:00 CEST | Press release
Fuel manufactured at Springfields has generated enough energy to supply the UK’s electricity demand for 26 years, avoiding the emission of nearly 3 billion tonnes of CO2 The Westinghouse Springfields facility in Lancashire, UK, has marked a significant milestone as the oldest continuous nuclear fuel manufacturing site in the world, starting from its original license on the 28th, March 1946. The site was chosen by the UK Government to develop nuclear fuel for the world’s earliest civil nuclear power stations, as well as subsequent Magnox and Advanced Gas Reactors (AGR) reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330135973/en/ From left to right: Sophie Lemaire; Marc Chevrel; Rory O'Neill; Craig Boothby; and Robert Gofton, CEO at Nuclear Institute Across the last eight decades, the Springfields site has supported the UK nuclear fleet, manufacturing more than eight million AGR pins, sintering and pressing over 5
HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)30.3.2026 14:00:00 CEST | Press release
HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. The Edison System is a novel, non-invasive, image guided platform that uses the mechanical properties of focused ultrasound, called histotripsy, to destroy unwanted tissue without the need for invasive procedures, and with potentially fewer side effects than traditional, invasive therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330349844/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics WOLVERINE is a prospective, multi-center, single-arm feasibility trial designed to evaluate
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
